Bristol Myers buys out cell therapy partner 2seventy bionews2025-03-11T07:13:39+00:00March 11th, 2025|Endpoints News|
BioNTech’s shares dip after posting lukewarm revenue guidancenews2025-03-10T18:37:01+00:00March 10th, 2025|Endpoints News|
Federal judge denies preliminary injunction in tirzepatide compounding casenews2025-03-10T16:48:58+00:00March 10th, 2025|Endpoints News|
Emergent sells once-troubled Baltimore site to Syngenenews2025-03-10T16:17:37+00:00March 10th, 2025|Endpoints News|
#AAD25 roundup: Data from Amgen, Bristol Myers, J&J, Alumis and morenews2025-03-10T15:37:26+00:00March 10th, 2025|Endpoints News|
Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibodynews2025-03-10T11:20:53+00:00March 10th, 2025|Endpoints News|
Mineralys’ Phase 3 blood pressure pill data support potential FDA approvalnews2025-03-10T11:01:30+00:00March 10th, 2025|Endpoints News|
Start of 2025 comes with generic drug price decreases, several major increases, report findsnews2025-03-07T20:17:00+00:00March 7th, 2025|Endpoints News|
FDA approves Neurotech therapy for rare eye disease news2025-03-07T19:57:13+00:00March 7th, 2025|Endpoints News|
Bayer eyes capital raise as it grapples with Monsanto casesnews2025-03-07T19:41:18+00:00March 7th, 2025|Endpoints News|
